glp-1 agonists cancer risk Glucagon-like peptide-1 receptor and of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials Glucagon-like peptide 1 receptor agonists

In another study conducted in a rat model of metabolic syndrome, chronic treatment with liraglutide showed a greater increase in coronary vessel internal diameter than vehicle control (Sukumaran et al., 2020)

Initially, three authors (CEBM, AFSR, and JC) formed the project coordinating committee

That said, Novo Nordisk and Eli Lilly aren't exactly sitting around doing nothing, so more GLP-1 developments are likely from this pair, as well

As with any medication, individual results can vary

These therapies differ by active ingredient, delivery method, dosing frequency, and FDA-approved indication

Oral formulations such as Rybelsus, which contains semaglutide, offer more comfort but still require careful dosing and often have gastrointestinal side effects